News
RXRX
--
0.00%
--
Berenberg Initiates Coverage On Recursion Pharmaceuticals with Buy Rating, Announces Price Target of $37
Berenberg analyst Gal Munda initiates coverage on Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy rating and announces Price Target of $37.
Benzinga · 4d ago
Berenberg Bank Initiates Coverage on Recursion Pharmaceuticals With Buy Rating, $37 Price Target
MT Newswires · 4d ago
Samsara BioCapital, LLC Buys Graphite Bio Inc, Centessa Pharmaceuticals PLC, Recursion ...
GuruFocus News · 08/24 22:38
Comprehensive Financial Management LLC Buys Recursion Pharmaceuticals Inc, Zymergen Inc, ...
GuruFocus News · 08/23 21:38
SVB Leerink Maintains Outperform on Recursion Pharmaceuticals, Lowers Price Target to $30
SVB Leerink analyst Mani Foroohar maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Outperform and lowers the price target from $33 to $30.
Benzinga · 08/16 09:40
BRIEF-Recursion Pharmaceuticals - Q2 Revenue $2.5 Mln Versus To $186,000 A Year Earlier
reuters.com · 08/13 11:59
Recursion Pharmaceuticals Q2 EPS $(0.31) Up From $(0.88) YoY
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.31) per share. This is a 64.77 percent increase over losses of $(0.88) per share from the same period last year.
Benzinga · 08/13 11:56
-- Earnings Flash (RXRX) RECURSION Posts Q2 Revenue $2.5M
MT Newswires · 08/13 08:09
Baillie Gifford & Co Buys The Trade Desk Inc, 10x Genomics Inc, Recursion Pharmaceuticals ...
GuruFocus News · 08/02 13:38
What You Need To Know About Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Investor Composition
The big shareholder groups in Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) have power over the company. Generally...
Simply Wall St. · 07/16 10:20
Prometheus Bio and Recursion Pharma on track to post record one-day losses
Mir Basar Suhaib/iStock via Getty Images Recently IPO’ed biotech firms Prometheus Biosciences ([[RXDX]] -21.5%) and Recursion Pharmaceuticals ([[RXRX]] -19.2%) are on course to record their biggest one-day losses since their
Seekingalpha · 07/14 19:43
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13)
Benzinga · 07/14 11:48
Stocks That Hit 52-Week Highs On Tuesday
    Before 10 a.m. ET on Tuesday, 128 companies hit new 52-week highs.
Benzinga · 07/13 15:42
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12)
Benzinga · 07/13 12:05
Recursion Reports Formation Of A Therapeutics Advisory Board
 Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced its
Benzinga · 07/13 11:59
Recursion forms Therapeutics Advisory Board
Recursion (RXRX) announces the formation of a Therapeutics Advisory Board ((TAB)), chaired by Joseph Miletich.Most recently, Miletich was Merck Research Laboratories' senior vice president of research sciences and is currently senior scientific advisor to
Seekingalpha · 07/13 11:59
Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced its formation of a Therapeutics Advisory Boa...
PR Newswire · 07/13 11:55
Recursion Opens Child Care Center to Support Employees
/PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced the opening of its child car...
PR Newswire - PRF · 07/12 20:41
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 07/09 11:36
Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, July 7, 2021: PATH, SGFY, RXRX, RPTX, QSI, MASS, FATE, COIN, TSLA, VUZI, FTCH, AVAV
UiPath (PATH) - 440,157 Shares Signify Health (SGFY) - 53,916 Recursion Pharmaceuticals (RXRX) - 204,752 Repare Therapeutics (RPTX) - 18,190 Quantum-Si (QSI) - 359,389 908 Devices (MASS) - 47,945 Fate
Benzinga · 07/08 13:23
Webull provides a variety of real-time RXRX stock news. You can receive the latest news about RECURSION PHARMACEUTICALS, INC. through multiple platforms. This information may help you make smarter investment decisions.
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company uses Recursion Operating System (Recursion OS), a multi-layer system for generating, analyzing and deriving insights from biological and chemical datasets. It consists of three parts: Infrastructure Layer, The Recursion Data Universe and The Recursion Map. Its programs include REC-4881, REC-3599, REC-2282, REC-994, lead molecules for the treatment of C. difficile Colitis, lead molecules for the treatment of Neuroinflammation, lead molecules for the treatment of Batten Disease and lead molecules for the treatment of CMT2A.